Stress-Induced Disease Modeling Using CD4+ T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective tools for researching and developing prevention and treatment strategies for diseases induced by stress, particularly chronic stress, which can lead to conditions like progressive multiple sclerosis, gastroenteritis, myocardial disorder, and sudden death, as the mechanisms from stress to disease onset are not fully elucidated.
Innovation Solution
A method involving non-human animals under stress conditions, where CD4 positive T cells reactive to central nervous tissue antigens are introduced, mimicking cerebrovascular inflammation, allowing for disease modeling and drug screening for these conditions, and using specific pharmaceuticals like antibodies to CCL5, GABA receptor agonists, and ATP receptor antagonists for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If CD4 positive T cells reactive to central nervous tissue antigens are introduced into non-human animals under stress conditions, then a useful disease modeling system for stress-induced diseases can be created, but the complexity of the experimental protocol increases
Solution Approach 1:
The disease modeling method is divided into distinct sequential steps: (1) inducing stress conditions in non-human animals, (2) introducing CD4 positive T cells reactive to central nervous tissue antigens, and (3) observing disease manifestation. This segmentation allows each step to be optimized and controlled independently, managing overall protocol complexity while maintaining comprehensive disease modeling capability.
Solution Approach 2:
Stress conditions are induced in the non-human animals before introducing the CD4 positive T cells. This preliminary action prepares the physiological environment in advance, ensuring that the animals are in the appropriate stress state to develop stress-induced diseases when the T cells are introduced, thereby enabling more reliable disease modeling.
2Reliability
If comprehensive disease modeling is performed to elucidate mechanisms from stress to disease onset, then effective prevention and treatment strategies can be developed, but the time and resources required for research increase
Solution Approach 1:
Non-human animals are used as copies or models of human physiological responses to stress. By inducing stress conditions and introducing CD4 positive T cells in these animal models, researchers can replicate human stress-induced disease mechanisms without directly studying human subjects, thereby reducing research time and ethical constraints while maintaining mechanistic reliability.
Solution Approach 2:
The disease modeling system using non-human animals with introduced CD4 positive T cells serves multiple research functions simultaneously: it can model various stress-induced diseases (including progressive multiple sclerosis, gastroenteritis, myocardial disorder, and sudden death), enable drug screening, and elucidate disease mechanisms. This multi-functionality reduces the need for separate experimental systems for different research objectives.
3Reliability
If specific pharmaceuticals are tested for treating stress-induced diseases, then effective treatments can be identified, but the cost and complexity of drug screening increase
Solution Approach 1:
The non-human animal model serves as an intermediary system between in vitro drug testing and clinical human trials. By using these animals with induced stress conditions and introduced CD4 positive T cells, pharmaceuticals can be screened in a physiologically relevant system that mimics human stress-induced diseases, providing reliable efficacy data while reducing the complexity and costs associated with direct human clinical trials.
Data Source
AI summary
[Problem] The objectives of the present invention are to provide a method for making an animal that has been stressed, in particular, chronically stressed, affect or develop a specific disease or symptom, and, through elucidating the process from loading stress to affection or onset of the disease or symptom, to provide a useful tool for research and development of preventing or treating methods of the disease or symptom. [Solution] The present invention relates to a method for producing a disease modeling non-human animal having cerebrovascular inflammation, the disease modeling non-human animal, a method for screening a drug using the disease modeling non-human animal, a method for determining the risk of a disease using the presence of cerebrovascular inflammation as an indicator, and a pharmaceutical for preventing and/or treating progressive multiple sclerosis or the like. The present invention enables developing pharmaceuticals for the above described diseases or the like and performing researches for elucidating their pathogenic mechanisms. The present invention also enables determining the risk of affection or onset of progressive multiple sclerosis or the like and preventing and/or treating progressive multiple sclerosis or the like.